Valuation: SpyGlass Pharma, Inc.

Market Cap 1.03B 928M 857M 777M 1.45B 98.17B 1.47B 10.27B 4.08B 51.46B 3.88B 3.8B 163B P/E 2026 *
-12.2x
P/E 2027 * -10.3x
Enterprise Value 1.03B 928M 857M 777M 1.45B 98.17B 1.47B 10.27B 4.08B 51.46B 3.88B 3.8B 163B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.72%
Yield 2026 *
-
Yield 2027 * -
1 day+3.31%
1 week+18.12%
Current month+18.85%
1 month+14.15%
3 months+48.41%
6 months+30.66%
1 week 26.68
Extreme 26.675
31.06
1 month 22.8
Extreme 22.795
31.06
Current year 17.06
Extreme 17.06
32.44
1 year 17.06
Extreme 17.06
32.44
3 years 17.06
Extreme 17.06
32.44
5 years 17.06
Extreme 17.06
32.44
10 years 17.06
Extreme 17.06
32.44
Manager TitleAgeSince
Chief Executive Officer 52 2021-06-30
President 51 2018-12-31
Director of Finance/CFO 60 2025-12-31
Director TitleAgeSince
Director/Board Member 54 2025-04-30
Director/Board Member 52 -
Director/Board Member 49 2019-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26
RA Capital Management LP
ConversionCompany 12,352,234 54.8107%
2/9/26
NEA Management Co. LLC
ConversionCompany 13,847,102 61.4439%
2/9/26
NEA Management Co. LLC
ConversionCompany 13,847,102 61.4439%
Change 5-day change 1-year change 3-year change Capi.($)
+3.31%+18.12% - - 1.03B
-3.10%-4.19%+32.67%+59.47% 63.48B
+0.33%+0.33%+10.16%+78.07% 54.55B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 44.75B
-1.30%-4.80%+16.05%+114.76% 41.62B
+1.26%-5.26%+221.12%+900.64% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+1.11%+15.18%+60.27%+49.33% 26.7B
+3.99%-5.95%+26.39%-8.00% 23.36B
Average +0.43%+0.74%+45.83%+154.66% 38.15B
Weighted average by Cap. -0.27%-1.22%+42.97%+155.32%

Financials

2026 *2027 *
Net sales - -
Net income -77.96M -69.97M -64.61M -58.59M -110M -7.41B -111M -775M -308M -3.88B -293M -286M -12.31B -103M -92.84M -85.73M -77.74M -145M -9.83B -147M -1.03B -408M -5.15B -388M -380M -16.33B
Net Debt - -
Projected Income Statement - Annual - SpyGlass Pharma, Inc.
Logo SpyGlass Pharma, Inc.
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
Employees
76
Date Price Change Volume
26-10-27 US$30.90 +3.31% 69,339
26-10-26 US$29.91 +5.02% 89,403
26-10-23 US$28.48 +0.92% 70,596
26-10-22 US$28.22 +1.84% 91,320
26-10-21 US$27.71 +5.93% 86,126
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - SpyGlass Pharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
30.90USD
Average target price
44.00USD
Spread / Average Target
+42.39%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - SpyGlass Pharma, Inc.